Clinical trials: Lymphatic System Neoplasm
Relapsed Acute Lymphoblastic Leukemia, Allergy to PEG e.Coli Asparaginase
Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)
This is a phase I study using the Erwinia form of asparaginase in place of the E. coli form using a standard re-induction regimen (Vincristine, Dexamethasone, Doxorubicin) for patients with relapsed ALL who have developed an…
- Conditions
- Relapsed Acute Lymphoblastic Leukemia, Allergy to PEG e.Coli Asparaginase, Allergy to Native e.Coli Asparaginase
- Trial name
- NCT00928200
- Testing
- Erwinase, Vincristine, Dexamethasone
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission
Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant
This randomized phase III trial is studying how well Caphosol rinse works in preventing mucositis in young patients undergoing autologous or donor stem cell transplant.
- Conditions
- Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes
- Trial name
- NCT01305200
- Testing
- supersaturated calcium phosphate rinse, questionnaire administration, quality-of-life assessment
- Where
- 35 sites in United States, Australia and 1 more
- Volunteers
- 226 people
- Sponsor
- Children's Oncology Group
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL
This study is to evaluate the safety and clinical activity of idelalisib alone and in combination with rituximab in patients with CLL or SLL.
- Trial name
- NCT01203930
- Testing
- Idelalisib, Rituximab
- Where
- 6 sites in United States
- Volunteers
- 105 people
- Sponsor
- Gilead Sciences
Diffuse Large B Cell Lymphoma
Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy
The purpose of this trial is to compare the efficacy and safety of Inotuzumab Ozogamicin in combination with R-CVP with that of R-G-CVP for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) in a population of patients not…
- Trial name
- INCA (NCT01679119)
- Testing
- Cyclophosphamide, Vincristine, Prednisolone
- Where
- 40 sites in United Kingdom
- Volunteers
- 129 people
- Sponsor
- University College, London
CD22 Positive, Recurrent Acute Lymphoblastic Leukemia
Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia
This phase II trial studies how well inotuzumab ozogamicin works in treating patients with CD22 positive acute lymphoblastic leukemia that has come back or does not respond to treatment.
- Conditions
- CD22 Positive, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
- Trial name
- NCT03094611
- Testing
- Inotuzumab Ozogamicin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Venous Thromboembolism, Multiple Myeloma
Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma
Patients living with multiple myeloma (MM) have an increased risk of venous thromboembolism (VTE) due to the disease itself and the use of targeted therapies, including immunomodulatory drugs (IMiDs).
- Trial name
- NCT02958969
- Testing
- Apixaban
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Gregory Piazza
Chronic Lymphocytic Leukemia
Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )
The primary objective of this study is to evaluate the effect of the addition of idelalisib (formerly GS-1101) to bendamustine + rituximab (BR) on progression-free survival (PFS) in participants with previously treated chronic…
- Trial name
- Tugela (NCT01569295)
- Testing
- Idelalisib, Rituximab, Bendamustine
- Where
- 106 sites in United States, Australia and 16 more
- Volunteers
- 416 people
- Sponsor
- Gilead Sciences
Follicular Lymphoma, Marginal Zone Lymphoma
Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma
Ofatumumab is a drug that works by attaching to the CD20 molecule found on the surface of cancerous B cells, and then triggering the death of those cells.
- Conditions
- Follicular Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma
- Trial name
- NCT01239394
- Testing
- ofatumumab
- Where
- 3 sites in United States
- Volunteers
- 43 people
- Sponsor
- Massachusetts General Hospital
Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood B-Lymphoblastic Lymphoma
Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
The overall objective of this protocol is to improve the cure rate of relapsed precursor B-cell acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma.
- Trial name
- NCT01700946
- Testing
- dexamethasone, vincristine sulfate, rituximab
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- St. Jude Children's Research Hospital
Lymphoma, B-cell Non-Hodgkin's Lymphoma
Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL
The purpose of this research is to study a treatment program for patients with aggressive lymphoma that has come back after initial or first therapy (called relapsed) or that has not responded to first therapy (called…
- Trial name
- NCT00588094
- Testing
- Rituximab, Ifosfamide, Carboplatin, VP-16, Mesna, G-CSF, Stem Cell Transplant
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hodgkin Lymphoma
Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma
The purpose of this study is to find out how safe and effective treatment with a new combination of drugs, mocetinostat and brentuximab vedotin, is in treating cancer.
- Trial name
- NCT02429375
- Testing
- Mocetinostat Plus Brentuximab Vedotin
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Bladder Cancer, Cervical Cancer
Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking
RATIONALE: Varenicline, the nicotine patch, and nicotine gum help people stop smoking. It is not yet known whether varenicline is more effective than the nicotine patch given together with nicotine gum in helping smokers quit…
- Conditions
- Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT00790569
- Testing
- nicotine, varenicline
- Where
- United States
- Volunteers
- 315 people
- Sponsor
- Butler Hospital
Multiple Myeloma
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
This randomized phase III trial studies melphalan and prednisone with thalidomide to see how well it works compared to melphalan and prednisone together with lenalidomide in treating patients with newly diagnosed multiple…
- Trial name
- NCT00602641
- Testing
- Laboratory Biomarker Analysis, Lenalidomide, Melphalan
- Where
- 391 sites in United States, Israel
- Volunteers
- 306 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, CLL
Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older
Primary Objective: To assess the activity of lenalidomide in patients with previously untreated chronic lymphocytic leukemia (CLL) age 65 and older.
- Conditions
- Leukemia, CLL, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Trial name
- NCT00535873
- Testing
- Lenalidomide
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- M.D. Anderson Cancer Center
Neoplasms Malignant
Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)
This is a Phase 1 trial evaluating the safety and efficacy of crizotinib in patients with tumors except non-small cell lung cancer that are positive for ALK.
- Trial name
- NCT01121588
- Testing
- Crizotinib
- Where
- 21 sites in United States, China and 5 more
- Volunteers
- 44 people
- Sponsor
- Pfizer
Leukemia, Chronic Lymphocytic Leukemia
CFAR Study in Patients With Chronic Lymphocytic Leukemia
Primary Objective: 1. Evaluate the ability of Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) to increase the proportion of patients with <5% CD5/CD19+ cells in bone marrow to 66% following 3 courses of treatment…
- Trial name
- NCT00525603
- Testing
- Cyclophosphamide, Fludarabine, Alemtuzumab
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Refractory Multiple Myeloma
Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma
This phase II trial is studying how well giving dinaciclib works in treating patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT01096342
- Testing
- dinaciclib, laboratory biomarker analysis
- Where
- 6 sites in United States, Singapore
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Hodgkin Disease, Lymphoma, Large-Cell, Anaplastic
Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics (PK) of brentuximab vedotin as a single agent in Chinese participants with relapsed/refractory CD30+ Hodgkin Lymphoma (HL) or Systemic Anaplastic…
- Trial name
- NCT02939014
- Testing
- Brentuximab Vedotin
- Where
- 7 sites in China
- Volunteers
- 39 people
- Sponsor
- Takeda
Pain
Safety and Tolerability of Zipsor® in Pediatric Subjects (Ages 12-17 Years) With Mild to Moderate Acute
As part of the PREA(Pediatric Research Equity Act) commitment, the objective of the study is to confirm safety and tolerability of 25 mg of Zipsor® in clinical pediatric subjects.
- Trial name
- NCT01982539
- Testing
- Zipsor®
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Depomed
Untreated Chronic Lymphocytic Leukemia
Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia
This is a randomized, multicenter, open-label, Phase 3 study to evaluate the efficacy and safety of Acalabrutinib versus Chlorambucil plus Rituximab in subjects with Previously Untreated Chronic Lymphocytic Leukemia.
- Trial name
- NCT04075292
- Testing
- Acalabrutinib, Rituximab, Chlorambucil
- Where
- 46 sites in China, Philippines and 3 more
- Volunteers
- 155 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.